Seattle Genetics begins Phase Ib RCC trial of SGN-75 – Pharmaceutical Business Review
Seattle Genetics begins Phase Ib RCC trial of SGN-75Pharmaceutical Business Review"We are encouraged by the preliminary single-agent activity and tolerability demonstrated by SGN-75 in RCC patients and by our preclinical data suggesting synergy be…